Patents Assigned to Q32 Bio Inc.
  • Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
    Patent number: 11879008
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: January 23, 2024
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
    Patent number: 11053305
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Fusion protein constructs comprising anti-C3d antibody and factor H
    Patent number: 11053306
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers